PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China.\', \'School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.\', \'The George Institute for Global Health, UNSW Sydney, Kensington, Australia.\', \'School of Health Policy & Management, Nanjing Medical University, Nanjing, Jiangsu, China.\', \'School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1111/bcp.14860
?:hasPublicationType
?:journal
  • British journal of clinical pharmacology
is ?:pmid of
?:pmid
?:pmid
  • 33855727
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.543
?:rankingScore_hIndex
  • 126
?:title
  • Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all